HIF1A and Miyoshi myopathy: More importantly, our data highlight the capacity of macitentan to interfere with the expression and release of pro-angiogenic cytokines, such as ET-1 itself, VEGF-A, IL-8 and ADM through the down-modulation of HIF-1α in MM cells.